Narrator: This is Science Today. A new, molecularly targeted drug has been found to extend the median survival rate of patients with advanced non-small cell lung cancer by twenty-two percent. Dr. Angela Davies of the University of California, Davis Medical Center, led this nationwide study.
Davies: This study demonstrated an eleven month median survival. When we compare the usual median survival for patients on front line chemotherapy trials, we were usually seeing survivals of about eight to nine months.
Narrator: The standard treatment for advanced lung cancer is two-drug combination chemotherapy. Davies and her colleagues added the drug bortezomib, which is currently used for a blood cancer called multiple myeloma, to get the boost in survival rates.
Davies: We now need to move forward with a randomized trial that would then compare the three drug combination to the two drug combination to determine whether this is something that should ultimately affect practice on a day-to-day basis.
Narrator: For Science Today, I'm Larissa Branin.